necessitated another extra HD. TA treatment was stopped, and because of persistent hyperkalaemia daily HDs of 4.5 h were continued for another 2 days. From A 30 year-old male haemodialysis ( HD) patient with this point gradual recovery of muscle strength and nephrotic syndrome and diabetic end-stage renal disgeneral well-being was obtained as well as relief from ease ( ESRD) presented with muscle pain from chest, muscle pain. Serum potassium returned to normal back and extremities (day 1). Clinical findings were values and the patient was discharged from hospital slight ankle oedema, basal pulmonary crepitation, and without any sequelae. tenderness of the muscles of back and lower extremities without signs of reduced muscle strength. Arterial blood pressure was 200/110-120 mmHg. Blood tests Background revealed slight hyponatraemia and a serum potassium of 6.4 mmol/l (normal range 3.6-4.9 mmol/l ). Other results were a haemoglobin of 12.5 g/dl. Blood leuko-TA, N-(2-methyl-3-chlorphenyl )-anthranilic acid, is a potent inhibitor of prostaglandin synthesis with an cyte and thrombocyte counts as well as serum concentrations of calcium, uric acid, creatine kinase, alanine additional inhibitory action on prostaglandin receptors. Pharmacokinetics are well described by a twoaminotransferase (ALAT ), bilirubin, lactate dehydrogenase (LDH ), and C-reactive protein were normal. compartment model with short half-lives, high protein binding, and small distribution volumes [1] . Its main S-alkaline phosphatase was slightly elevated, possibly, because of previous treatment with valproic acid. The elimination pathway is hepatic biotransformation by cytochrome P-450-mediated oxidation. Glucuronic patient was hospitalized and treated with symptomatic analgetics including paracetamol, buprenorphine, and tramadol. An oral supplement of calcium-resonium The general profile of adverse drug reactions related to treatment with NSAIDs-gastropathy, renal toxicity, skin reactions, and more rarely liver toxicity or pulmonary alveolitis-also seems to apply to TA with the exception of gastrointestinal adverse reactions being more rare.
In the kidneys, the major cortical prostaglandin, PGI 2 , exerts an important positive influence on glomerular filtration rate (GFR), whereas PGE 2 inhibits tubular vasopressin responsiveness and sodium reabsorption in the thick ascending limb of the loop of Henle, thus promoting natriuresis and water excretion. Renin release is in part controlled by PGI 2 . Mineralocorticoids are essential for the renal handling of potassium but may also be of importance in the regulation of extrarenal potassium deposition [3] .
HD does not affect plasma concentrations of NSAIDs, probably because of their high degree of protein binding.
Discussion
Renal side-effects to NSAIDs are well documented. Altered handling of NSAIDs might be expected in patients with liver disease (cirrhosis). In patients with renal dysfunction, NSAID metabolites will accumulate [2] and the free fraction of tolfenamic acid in blood is increased [4] . Patients with lupus nephritis or nephrotic syndrome are especially susceptible to adverse reactions of NSAIDs [5] . Other factors that predispose to functional renal impairment during treatment with NSAIDs include hypertension, volume depletion, diuretic therapy, diabetes mellitus (DM ), myeloma, gouty arthritis, sepsis, anaesthesia and prematurity with patent ductus arteriosus [6 ] .
Muscle paralysis is a rare complication to severe hyperkalaemia. Freeman and Fale [7] reported a case of hyperkalaemia and progressive muscular paralysis with repiratory embarrassment in a 75-year-old male diabetic after 1 week's treatment with amiloridehydrochlorothiazide. Reversible profound muscle weakness from severe hyperkalaemia has also been reported in two HD patients who had been dialysed against a dialysate potassium concentration of 10 mmol/l [8]. To our knowledge, however, severe hyperkalaemia with paralysis following treatment with a prostaglandin inhibitor has not previously been described with a HD patient.
In the present case no other reason was found for the patient's acute illness than the possible adverse reaction to treatment with TA. A possible mechanism might involve reduction of residual GFR and water excretion, in combination with inhibition of renin and aldosterone release and reduced Na,K pump activity. The medication already included an ACE inhibitor, but several studies show that the initial reduction in Table 2 . Laboratory results and haemodialysis #Blood tests 6-1 to 6-3 taken at 7.25 a.m., 3.00 p.m., and 8.00 p.m. respectively.
